MOA Life Plus Co. Ltd.

A142760

KR7142760008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3,830 ^KRW	+7.28%		+20.25%	+79.81%

Apr. 15	Bioleaders Corporation announced that it has received KRW 10 billion in funding from Moadata Co., Ltd.	CI
Mar. 29	Bioleaders Corporation announced that it has received KRW 15 billion in funding	CI

Next Bt Co., Ltd. acquired 2.76% stake in Bioleaders Corporation for KRW 8 billion.

April 23, 2018

Next Bt Co., Ltd. (KOSDAQ:A065170) acquired 2.76% stake in Bioleaders Corporation (KOSDAQ:A142760) for KRW 8 billion on April 23, 2018. Under the terms of the transaction, Next Bt Co., Ltd. acquired 0.44 million shares.

Next Bt Co., Ltd. (KOSDAQ:A065170) completed the acquisition of 2.76% stake in Bioleaders Corporation (KOSDAQ:A142760) on April 23, 2018.

Latest news about MOA Life Plus Co. Ltd.

Bioleaders Corporation announced that it has received KRW 10 billion in funding from Moadata Co., Ltd.	Apr. 14	CI
Bioleaders Corporation announced that it has received KRW 15 billion in funding	Mar. 28	CI
Youngchul Park completed the acquisition of 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation.	Mar. 27	CI
Moadata Co., Ltd. completed the acquisition of 6.95% stake in Bioleaders Corporation from Youngchul Park.	Mar. 27	CI
Bioleaders Corporation announced that it expects to receive KRW 15 billion in funding	Mar. 13	CI
Moadata Co., Ltd. agreed to acquire a 6.95% stake in Bioleaders Corporation from Youngchul Park for KRW 15.3 billion	Mar. 12	CI
Bioleaders Corporation announced that it expects to receive KRW 10 billion in funding from Moadata Co., Ltd.	Mar. 11	CI
Youngchul Park agreed to acquire 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation for KRW 9.3 billion.	Mar. 11	CI
Bioleaders Corporation announced that it has received KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.	Jan. 01	CI
An unknown buyer agreed to acquire 20.25052% stake in Anyone F&C Co., Ltd. from Bioleaders Corporation for KRW9.9 billion.	Dec. 28	CI
Bioleaders Corporation announced that it expects to receive KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.	Dec. 28	CI
Bioleaders Corporation(KOSDAQ:A142760) dropped from S&P Global BMI Index	23-09-18	CI
Bioleaders Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Next Bt Co., Ltd. announced that it has received KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors	21-11-30	CI
Bioleaders Corporation announced that it has received KRW 13 billion in funding from Blash Asset Management Co., Ltd, Tiger Asset Management Discretionary Investment Co., Ltd., and other investors	21-11-30	CI
Bioleaders Corporation announced that it has received KRW 8 billion in funding	21-11-30	CI
Bioleaders Corporation announced that it expects to receive KRW 8 billion in funding from Blash Asset Management Co., Ltd, Tiger Asset Management Discretionary Investment Co., Ltd., and other investors	21-11-28	CI
Bioleaders Corporation announced that it expects to receive KRW 8 billion in funding	21-11-28	CI
Next Bt Co., Ltd. announced that it expects to receive KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors	21-11-28	CI
Bioleaders Corporation announced that it has received KRW 13 billion in funding from C-Square Asset Management, A One Asset Management Co., Ltd, Bluetech Asset Management Co., Ltd., Mirae Asset Daewoo Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm and other investors	21-02-17	CI
Bioleaders Corporation announced that it has received KRW 10.0000159 billion in funding from Asset One Asset Management	21-02-17	CI
Bioleaders Corporation announced that it expects to receive KRW 13 billion in funding from C-Square Asset Management, A One Asset Management Co., Ltd, Bluetech Asset Management Co., Ltd., Mirae Asset Daewoo Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm and other investors	21-02-15	CI
Bioleaders Corporation announced that it expects to receive KRW 10.0000159 billion in funding from Asset One Asset Management	21-02-08	CI
Bioleaders Corporation announced that it has received KRW 7.1 billion in funding	19-04-25	CI
Bioleaders Corporation announced that it has received KRW 4 billion in funding from Hana Financial Investment Co., Ltd., Meritz Securities Co., Ltd. and another investor	19-03-28	CI

Chart MOA Life Plus Co. Ltd.

Duration

Period

More charts

Company Profile

Moa Life Plus, formerly BL Corp, is a Korea-based company primarily engaged in the research and development of biotechnology and biopharmaceuticals. The Company is engaged in the manufacture and sale of health functional foods and functional cosmetics. In addition, the Company is engaged in the distribution of pharmaceuticals and medical supplies. The Company is engaged in the development of cervical cancer treatment, anticancer drugs and other products.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MOA LIFE PLUS CO. LTD.	+79.81%	91.09M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B